Skip to main content

Clinical Trials to Treat Kidney (Renal Cell) Cancer

Trials 51-75 of 124

Implantable Microdevice for the Delivery of Microdoses of Drugs to the Tumor in Patients with Metastatic Renal Cell Cancer
Status: Active
Location: 2 locations
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Status: Active
Location: 2 locations
Stereotactic Body Radiation Therapy with Nivolumab and BMS986253 for the Treatment of Multiple Metastases in Patients with Advanced Solid Tumors
Status: Active
Location: 2 locations
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Status: Active
Location: 2 locations
Cytokine Induced Memory-Like Natural Killer Cells in Combination with Aldesleukin for the Treatment of Locally Advanced or Metastatic Renal Cell Cancer or Urothelial Cancer
Status: Active
Location: 2 locations
Proton-Based Stereotactic Body Radiation Therapy for the Treatment of Renal Cell Cancer in Patients not Undergoing Surgery
Status: Active
Location: 2 locations
Comparison of In-Home versus In-Clinic Administration of Subcutaneous Nivolumab through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Local Consolidative Therapy to Extend the Efficacy of Systemic Therapy in Oligoprogressive Metastatic Cancer, EXTEND-OP Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Pembrolizumab after Radiation Therapy for the Treatment of Patients with Oligometastatic Renal Cell Cancer, ASTROs Study
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Dendritic Cell Vaccine in Combination with Cabozantinib for Altering the Immune System in Patients with Localized Clear Cell Renal Cell Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Molecular Residual Disease-Guided Treatment of Renal Cell Carcinoma, MRD GATE RCC Trial
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Belzutifan versus Active Surveillance for the Treatment of Metastatic Clear Cell Renal Cell Cancer, BRAVE-ROC Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
STING Agonist (IMSA101) and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy with Nivolumab for the Treatment of Stage IV Renal Cell Carcinoma in Patients who Progressed on Immunotherapy, SPARK Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Olaparib for Treatment of Metastatic Kidney Cancer in Patients with DNA Repair Gene Mutations, the ORCHID Study
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Belzutifan or Pembrolizumab Alone versus in Combination for Neoadjuvant Treatment of Clear Cell Renal Cell Cancer, BLAZE Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Neoadjuvant Zanzalintinib Plus Nivolumab for the Treatment of Locally Advanced and/or Inoperable Clear Cell Renal Cell Cancer, EXPLORE-RCC Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Ivonescimab for the Treatment of Previously Treated Metastatic/Advanced Clear Cell Renal Cell Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Neoadjuvant Lenvatinib and Pembrolizumab for the Treatment of Stage III-IV Kidney Cancer and Inferior Vena Cava Tumor Thrombus
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Nivolumab, Ipilimumab, and Cabozantinib for the Treatment of Untreated Renal Cell Carcinoma with Brain Metastases
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Single- or Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
High Dose Cabozantinib for the Treatment of Locally Advanced, Unresectable, or Metastatic Progressive Renal Cell Carcinoma, The Seq-Cabo Trial
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Ubamatamab Alone or in Combination with Cemiplimab for Patients with Locally Advanced or Metastatic Renal Medullary Carcinoma or Epithelioid Sarcoma that is MUC16-Expressing SMARCB1-Deficient
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland